$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

$hyex Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000109690622001904 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$499.7K	$469.8K	$671.6K
YoY Change	31.53%	92.64%	394.18%
Cost Of Revenue	$68.55K	$195.6K	$198.7K
YoY Change	-5.12%	479.18%	-85.93%
Gross Profit	$431.1K	$274.3K	$472.9K
YoY Change	40.14%	30.52%	-137.06%
Gross Profit Margin	86.28%	58.38%	70.41%
Selling, General & Admin	$485.6K	$961.1K	$710.4K
YoY Change	-29.93%	92.44%	84.18%
% of Gross Profit	112.64%	350.43%	150.23%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$330.00		$1.270K
YoY Change	-74.22%		-42.53%
% of Gross Profit	0.08%		0.27%
Operating Expenses	$485.6K	$888.4K	$710.4K
YoY Change	-29.93%	91.12%	84.18%
Operating Profit	-$54.47K	-$614.1K	-$237.5K
YoY Change	-85.86%	141.12%	-85.71%
Interest Expense	-$115.8K	-$245.2K	$1.199M
YoY Change	-64.6%	-19.09%	49436.78%
% of Operating Profit
Other Income/Expense, Net	-$115.8K	-$245.2K
YoY Change		-19.09%
Pretax Income	-$170.2K	-$859.3K	$536.7K
YoY Change	-74.69%	54.07%	-132.94%
Income Tax
% Of Pretax Income
Net Earnings	-$170.2K	-$859.3K	$536.7K
YoY Change	-74.69%	54.07%	-132.94%
Net Earnings / Revenue	-34.07%	-182.91%	79.92%
Basic Earnings Per Share
Diluted Earnings Per Share	-$498.30	-$2.528K	$1.653K
COMMON SHARES
Basic Shares Outstanding	344.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$73.88K	$159.4K	$222.1K
YoY Change	-35.83%	-44.44%	275.17%
Cash & Equivalents	$73.88K	$159.4K	$222.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$1.866M	$1.869M	$1.958M
Prepaid Expenses
Receivables	$100.8K	$100.2K	$133.3K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.041M	$2.129M	$2.313M
YoY Change	-25.29%	-26.82%	-7.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.050K	$6.600K	$1.040K
YoY Change	161.9%	83.84%	-83.06%
Goodwill		$193.3K	$193.3K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.89K	$16.89K	$0.00
YoY Change
Total Long-Term Assets	$738.1K	$738.6K	$716.2K
YoY Change	4.49%	6.11%	14.54%
TOTAL ASSETS
Total Short-Term Assets	$2.041M	$2.129M	$2.313M
Total Long-Term Assets	$738.1K	$738.6K	$716.2K
Total Assets	$2.779M	$2.867M	$3.030M
YoY Change	-19.17%	-20.46%	-2.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$114.1K	$114.1K	$37.27K
YoY Change	392.53%	675.41%	-42.52%
Accrued Expenses	$36.61K	$7.784K	$59.26K
YoY Change	-61.25%	-92.99%	395.93%
Deferred Revenue
YoY Change
Short-Term Debt	$454.8K	$508.2K	$342.6K
YoY Change	-56.09%	-44.92%	92.89%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$944.3K	$896.2K	$558.8K
YoY Change	-61.43%	-55.98%	113.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$944.3K	$896.2K	$558.8K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$944.3K	$896.2K	$558.8K
YoY Change	-61.43%	-55.98%	113.62%
SHAREHOLDERS EQUITY
Retained Earnings		-$15.80M	-$14.94M
YoY Change
Common Stock		$344.5K	$338.4K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.835M	$1.971M	$2.471M
YoY Change
Total Liabilities & Shareholders Equity	$2.779M	$2.867M	$3.030M
YoY Change	-19.17%	-20.46%	-2.76%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$170.2K	-$859.3K	$536.7K
YoY Change	-74.69%	54.07%	-132.94%
Depreciation, Depletion And Amortization	$330.00		$1.270K
YoY Change	-74.22%		-42.53%
Cash From Operating Activities	-$86.34K	-$46.27K	$40.88K
YoY Change	-68.41%	37.63%	-95.85%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$11.11K
YoY Change	-100.0%	-100.0%	-89.94%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00	-$11.11K
YoY Change	-100.0%	-100.0%	-104.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	820.0	113.4K	77.20K
YoY Change	-99.27%	-7.9%	-104.93%
NET CHANGE
Cash From Operating Activities	-86.34K	-46.27K	40.88K
Cash From Investing Activities	0.000	0.000	-11.11K
Cash From Financing Activities	820.0	113.4K	77.20K
Net Change In Cash	-85.52K	67.12K	107.0K
YoY Change	-50.22%	24.3%	-133.4%
FREE CASH FLOW
Cash From Operating Activities	-$86.34K	-$46.27K	$40.88K
Capital Expenditures	$0.00	$0.00	-$11.11K
Free Cash Flow	-$86.34K	-$46.27K	$51.99K
YoY Change	-67.02%	-245.82%	-95.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55572
	dei	Entity Registrant Name EntityRegistrantName	Healthy Extracts Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2594704
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Silvermound
	dei	Entity Address City Or Town EntityAddressCityOrTown	Littleton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80127
	dei	Country Region CountryRegion	720
	dei	City Area Code CityAreaCode	463
	dei	Local Phone Number LocalPhoneNumber	1004
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	344832442	shares
CY2022Q2	us-gaap	Cash Cash	159405	usd
CY2021Q4	us-gaap	Cash Cash	222098	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100192	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	133340	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1869088	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1957966	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2128685	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2313404	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	45944	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	36895	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6598	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1035	usd
CY2022Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2022Q2	us-gaap	Deposits Assets DepositsAssets	16890	usd
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	0	usd
CY2022Q2	us-gaap	Goodwill Goodwill	193260	usd
CY2021Q4	us-gaap	Goodwill Goodwill	193260	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	738629	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	716175	usd
CY2022Q2	us-gaap	Assets Assets	2867313	usd
CY2021Q4	us-gaap	Assets Assets	3029579	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	114141	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	37267	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7784	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59264	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	866	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	170866	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	507337	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	171750	usd
CY2022Q2	fil	Convertible Debt Related Party Net Of Discount ConvertibleDebtRelatedPartyNetOfDiscount	0	usd
CY2021Q4	fil	Convertible Debt Related Party Net Of Discount ConvertibleDebtRelatedPartyNetOfDiscount	0	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	14683	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	13050	usd
CY2022Q2	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	17031	usd
CY2021Q4	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	14118	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	234365	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	92527	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	896208	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	558841	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	344491821	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	344491821	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	338887410	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	338887410	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	344492	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	338384	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17426549	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17075974	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15799935	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14943620	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1971105	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2470738	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2867313	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3029579	usd
CY2022Q2	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	542484	usd
CY2021Q2	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	278458	usd
CY2022Q2	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	1094138	usd
	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	459492	usd
CY2022Q2	us-gaap	Selling Expense SellingExpense	72673	usd
CY2021Q2	us-gaap	Selling Expense SellingExpense	34572	usd
	us-gaap	Selling Expense SellingExpense	160940	usd
	us-gaap	Selling Expense SellingExpense	45173	usd
CY2022Q2	us-gaap	Revenues Revenues	469812	usd
CY2021Q2	us-gaap	Revenues Revenues	243886	usd
	us-gaap	Revenues Revenues	933198	usd
	us-gaap	Revenues Revenues	414318	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	195556	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33764	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	334238	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	75206	usd
CY2022Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2021Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	195556	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	33764	usd
	us-gaap	Cost Of Revenue CostOfRevenue	334238	usd
	us-gaap	Cost Of Revenue CostOfRevenue	75206	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	274255	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	210122	usd
	us-gaap	Gross Profit GrossProfit	598960	usd
	us-gaap	Gross Profit GrossProfit	339112	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	888401	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	464831	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1258758	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1180918	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	888401	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	464831	usd
	us-gaap	Operating Expenses OperatingExpenses	1258758	usd
	us-gaap	Operating Expenses OperatingExpenses	1180918	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-24365	usd
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-13597	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-57322	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-29356	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-220817	usd
CY2021Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-289445	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-141839	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-980225	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q2	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2021Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	2643	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-245181	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-303041	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-196517	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1009581	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-859326	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-557751	usd
	us-gaap	Profit Loss ProfitLoss	-856315	usd
	us-gaap	Profit Loss ProfitLoss	-1851387	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-859326	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-557751	usd
	us-gaap	Net Income Loss NetIncomeLoss	-856315	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1851387	usd
CY2022Q2	fil	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.00
CY2021Q2	fil	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.00
	fil	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.00
	fil	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.01
CY2022Q2	fil	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	339980360	shares
CY2021Q2	fil	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	315764537	shares
	fil	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	342254631	shares
	fil	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	317043903	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2853826	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45000	usd
CY2021	fil	Stock Issued During Period Value New Issues2 StockIssuedDuringPeriodValueNewIssues2	15000	usd
CY2021	fil	Stock Issued During Period Value New Issues3 StockIssuedDuringPeriodValueNewIssues3	165000	usd
CY2021	fil	Stock Issued During Period Value New Issues4 StockIssuedDuringPeriodValueNewIssues4	0	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	86400	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51480	usd
CY2021	fil	Stock Issued During Period Value Issued For Services2 StockIssuedDuringPeriodValueIssuedForServices2	144000	usd
CY2021	fil	Stock Issued During Period Value Issued For Services3 StockIssuedDuringPeriodValueIssuedForServices3	60000	usd
CY2021	fil	Stock Issued During Period Value Issued For Services4 StockIssuedDuringPeriodValueIssuedForServices4	91956	usd
CY2021	fil	Debt Conversion Converted Instrument Amount12 DebtConversionConvertedInstrumentAmount12	60000	usd
CY2021	fil	Stock Issued During Period Value Issued For Services5 StockIssuedDuringPeriodValueIssuedForServices5	175000	usd
CY2021	fil	Issuance Of Common Stock For Cash5 IssuanceOfCommonStockForCash5	100000	usd
CY2021	fil	Debt Conversion Converted Instrument Amount13 DebtConversionConvertedInstrumentAmount13	610199	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1987122	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2470738	usd
	fil	Cancelation Of Common Stock For Debt CancelationOfCommonStockForDebt	-10013	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25396	usd
	fil	Cancelation Of Common Stock For Debt1 CancelationOfCommonStockForDebt1	-43800	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	64000	usd
	fil	Stock Issued During Period Value Issued For Services6 StockIssuedDuringPeriodValueIssuedForServices6	57100	usd
	fil	Depreciation And Amortization1 DepreciationAndAmortization1	2550	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	422300	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	341880	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	141839	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	980225	usd
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
	fil	Stock Issued During Period Value Issued For Services7 StockIssuedDuringPeriodValueIssuedForServices7	264000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-856315	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1971105	usd
	us-gaap	Net Income Loss NetIncomeLoss	-856315	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1851387	usd
	fil	Depreciation And Amortization1 DepreciationAndAmortization1	-219	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-2643	usd
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33148	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27040	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-88877	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	164018	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-16890	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	76874	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-50113	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-51479	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	80664	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1633	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	11602	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2913	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6762	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-154676	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-668875	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7987	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	fil	Purchase Of Note Receivable PurchaseOfNoteReceivable	0	usd
	fil	Purchase Of Note Receivable PurchaseOfNoteReceivable	0	usd
	fil	Increase Decrease In Trademarks IncreaseDecreaseInTrademarks	0	usd
	fil	Increase Decrease In Trademarks IncreaseDecreaseInTrademarks	-73388	usd
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7987	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73388	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
	fil	Purchase Of Ubn PurchaseOfUbn	0	usd
	fil	Purchase Of Ubn PurchaseOfUbn	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-65617	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	225000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	539000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	745000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	203413	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	0	usd
	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-170000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	99970	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	970000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62693	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	227738	usd
CY2021Q4	us-gaap	Cash Cash	222098	usd
CY2020Q4	us-gaap	Cash Cash	59201	usd
CY2022Q2	us-gaap	Cash Cash	159405	usd
CY2021Q2	us-gaap	Cash Cash	286939	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:10pt Times New Roman;margin:0;text-align:justify"><b><i>Use of Estimates</i></b></p> <p style="font:10pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2022Q2	fil	Inventory Allowances InventoryAllowances	1914891	usd
CY2021Q4	fil	Inventory Allowances InventoryAllowances	1543758	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font:10pt Times New Roman;margin:0;text-align:justify"><b><i>Concentration</i></b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">There is no concentration of revenue for the six months ended June 30, 2021 and for the six months ended June 30, 2022 because the revenue was earned from multiple customers.</span></p>
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	92527	usd
	fil	Convertible Debt Issued ConvertibleDebtIssued	142704	usd
	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	-866	usd
	fil	Convertible Debt Converted ConvertibleDebtConverted	0	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	234365	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15799935	usd
CY2022Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1000	usd
CY2021Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	36000	usd
CY2022Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	17897	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	17031	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	507337	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	507337	usd
CY2022Q2	fil	Convertible Debt Accrued Interest ConvertibleDebtAccruedInterest	11485	usd
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares

Files In Submission

Name	View Source	Status
0001096906-22-001904-index-headers.html	Edgar Link	pending
0001096906-22-001904-index.html	Edgar Link	pending
0001096906-22-001904.txt	Edgar Link	pending
0001096906-22-001904-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hyex-20220630.htm	Edgar Link	pending
hyex-20220630.xsd	Edgar Link	pending
hyex10q_1.jpg	Edgar Link	pending
hyex_ex31z1.htm	Edgar Link	pending
hyex_ex31z2.htm	Edgar Link	pending
hyex_ex32z1.htm	Edgar Link	pending
hyex_ex32z2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
hyex-20220630_cal.xml	Edgar Link	unprocessable
hyex-20220630_def.xml	Edgar Link	unprocessable
hyex-20220630_lab.xml	Edgar Link	unprocessable
hyex-20220630_pre.xml	Edgar Link	unprocessable
hyex-20220630_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

2022 Q3 Form 10-Q Financial Statement

#000109690622001904 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX HEALTHY EXTRACTS INC. Stock $hyex

2022 Q3 Form 10-Q Financial Statement

#000109690622001904 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex